More on CCCC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.03 |
|
|||
| Open | $2.95 | ||||
| 52 Wk High | $0.30 | ||||
| 52 Wk Low | $0.30 | ||||
| Day High | $3.12 | ||||
| Day Low | $2.85 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 1,845,237 | ||||
- C4 Therapeutics (CCCC) PT Raised to $7 at Barclays
- TD Cowen Reiterates Buy Rating on C4 Therapeutics (CCCC)
- Form S-8 C4 Therapeutics, Inc.
- Form 10-K C4 Therapeutics, Inc. For: Dec 31
- Form 8-K C4 Therapeutics, Inc. For: Feb 26
- C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- C4 Therapeutics (CCCC) PT Raised to $30 at Brookline Capital Markets
- C4 Therapeutics to Participate in Upcoming March Conferences
- C4 Therapeutics begins phase 2 trial for multiple myeloma drug
- C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
Entities mentioned with CCCC
- FDA | View Related Stories »
- 13G | View Related Stories »
- Earnings | View Related Stories »
- JPMorgan | View Related Stories »
- Jefferies & Co | View Related Stories »
- IPO | View Related Stories »
- UBS | View Related Stories »
- Cowen & Co | View Related Stories »
- Show More...
